Stellungnahme zur Nutzenbewertung von Dupilumab (Eosinophile Ösophagitis)

Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS), Gesellschaft für Pädiatrische Gastroenterologie und Ernährung (GPGE) und die Deutsche Gesellschaft für Neurogastroenterologie und Motilität (DGNM)

Publication History

Article published online:
07 September 2023

• Literatur

• 1 Straumann A, Spichtin HP, Bernoulli R. et al. Idiopathische, eosinophile Osophagitis: eine häufig verkannte Krankheit mit typischer Klinik und diskretem endoskopischem Bild. Schweiz Med Wochenschr 1994; 124: 1419-1429
• 2 Attwood SE, Smyrk TC, Demeester TR. et al. Esophageal eosinophilia with dysphagia. A Esophageal eosinophilia with dysphagia. A distinct clinicopathologic syndrome. Dig Dis Sci 1993; 38: 109-116
• 3 Navarro P, Arias Á, Arias-González L. et al. Systematic review with meta-analysis: the growing incidence and prevalence of eosinophilic oesophagitis in children and adults in population-based studies. Aliment Pharmacol Ther 2019; 49: 1116-1125
• 4 Hahn JW, Lee K, Shin JI. et al. Global Incidence and Prevalence of Eosinophilic Esophagitis, 1976–2022: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol 2023; 10
• 5 Madisch A, Koop H, Miehlke S. et al. S2k-Leitlinie Gastroösophageale Refluxkrankheit und eosinophile Ösophagitis der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS). Z Gastroenterol 2023; 61: 862-933
• 6 Lucendo AJ, Molina-Infante J, Arias Á. et al. Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults. United European Gastroenterol J 2017; 5: 335-358
• 7 Spergel JM, Brown-Whitehorn TF, Beausoleil JL. et al. 14 years of eosinophilic esophagitis: clinical features and prognosis. Journal of pediatric gastroenterology and nutrition 2009; 48: 30-36
• 8 Warners MJ, Oude NijhuisRAB, Wijkerslooth LRH de. et al. The natural course of eosinophilic esophagitis and long-term consequences of undiagnosed disease in a large cohort. The American journal of gastroenterology 2018; 113: 836-844
• 9 Dellon ES, Lucendo AJ, Schlag C. et al. Fluticasone Propionate Orally Disintegrating Tablet (APT-1011) for Eosinophilic Esophagitis: Randomized Controlled Trial. Clin Gastroenterol Hepatol 2022; 20: 2485-2494.e15
• 10 Straumann A, Conus S, Degen L. et al. Long-term budesonide maintenance treatment is partially effective for patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol 2011; 9: 400-409.e1
• 11 Straumann A, Lucendo AJ, Miehlke S. et al. Budesonide Orodispersible Tablets Maintain Remission in a Randomized, Placebo-Controlled Trial of Patients With Eosinophilic Esophagitis. Gastroenterology 2020; 159: 1672-1685.e5
• 12 Safroneeva E, Coslovsky M, Kuehni CE. et al. Eosinophilic oesophagitis: relationship of quality of life with clinical, endoscopic and histological activity. Aliment Pharmacol Ther 2015; 42: 1000-1010
• 13 Arnim von U, Biedermann L, Aceves SS. et al. Monitoring Patients With Eosinophilic Esophagitis in Routine Clinical Practice – International Expert Recommendations. Clin Gastroenterol Hepatol 2022;
• 14 Kuchen T, Straumann A, Safroneeva E. et al. Swallowed topical corticosteroids reduce the risk for long-lasting bolus impactions in eosinophilic esophagitis. Allergy 2014; 69: 1248-1254
• 15 Schlag C, Straumann A, Lucendo AJ. Stephen Attwood on behalf of the international EOS-2 study group. et al Budesonide orodispersible tablets maintain clinical, histological and endoscopic remission in adult patients with eosinophilic esophagitis: Results from the 96-weeks open-label extension phase following the 1-year double-blind EOS-2 trial. Digestive Disease week 2023
• 16 Lucendo AJ, Arias Á, Molina-Infante J. Efficacy of Proton Pump Inhibitor Drugs for Inducing Clinical and Histologic Remission in Patients With Symptomatic Esophageal Eosinophilia: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol 2016; 14: 13-22.e1